Eneboparatide not checked
Alexion Pharmaceuticals, Inc. · AZP-3601
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens”In the company’s words, NCT05778071 on ClinicalTrials.gov
- Main trialPhase 3
- “This study is investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP). During the first 24 weeks of the trial, participants will be randomized to receive eneboparatide or placebo. Study treatment is blinded: patients and doctors will not know which group each patient has been randomized to. All patients will start with a fixed dose of study treatment (eneboparatide or placebo), administered subcutaneously with a pre-filled pen. Study treatment will be individually titrated. After completion of the first 24 weeks, patients will be…”In the company’s words, NCT05778071 on ClinicalTrials.gov
- Other names
- AZP-3601
Other drugs for Chronic Hypoparathyroidism
- PalopegteriparatideAscendis Pharma A/S · Phase 3
- CanvuparatideMBX Biosciences · Phase 3
- EncaleretCalcilytix Therapeutics, Inc., a BridgeBio company · Phase 3
- AMOR-1Amorphical Ltd. · Phase 2
- EXT608Extend Biosciences Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Nov 2024 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | |
| Phase 1/2Completed | 23 Aug 2022 | AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026